【レポートの概要（一部）】
1. Report Overview
1.1 The Prostate Cancer Therapeutics Market Overview
1.2 Prostate Cancer Therapeutics Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Prostate Cancer
2.1 What is Cancer?
2.2 Phenotypic Characteristics of Cancer Cells
2.2.1 Uncontrollable Growth
2.2.2 Loss of Apoptosis Pathways
2.2.3 Lack Differentiation
2.2.4 Increased Angiogenesis
2.2.5 Potential for Metastasis
2.2.6 Genetic Instability
2.3 What Causes Cancer?
2.4 Worldwide Prevalence of Cancer: A Global Picture
2.5 What is Prostate Cancer?
2.6 Worldwide Prevalence of Prostate Cancer: Rapid Global Growth
2.7 Risk Factors for Prostate Cancer
2.8 How is Prostate Cancer Diagnosed?
2.8.1 PSA Testing
2.8.2 Digital Rectal Examination Testing
2.8.3 Prostate Cancer Screening: Beneficial or Costly?
2.8.4 Newly Approved Tests May Improve Diagnosis
2.8.4.1 Prostate Cancer Diagnostics in the Pipeline
2.9 Treatment Sequence for Prostate Cancer
2.9.1 Localised Prostate Cancer: Surgery/Radiation is Most Preferred
2.9.1.1 Brachytherapy
2.9.1.2 Radical Prostatectomy
2.9.1.3 External Beam Radiation Therapy
2.9.1.4 Cryotherapy
2.9.1.5 High-Intensity Focussed Ultrasound (HIFU)
2.9.2 Advanced Local or Metastatic Prostate Cancer: Androgen Deprivation Therapy
2.9.3 Non-Metastatic CRPC: Ketoconazole and Anti-Androgens
2.9.4 Metastatic CRPC: Expanding the Standard Taxotere Treatment Paradigm
2.9.5 First Line Chemotherapy: Docetaxel is a Standard Treatment
2.9.6 Post Docetaxel Therapy: Five FDA Approved Drugs
2.9.7 Second Line Chemotherapy: Jevtana Approved in 2010
3. The Prostate Cancer Therapeutics Market 2014-2024
3.1 The Global Prostate Cancer Therapeutics Market, 2013
3.2 The Global Prostate Cancer Therapeutics Market Forecast, 2014-2024
3.3 The Global Prostate Cancer Therapeutics Market: Drivers and Restraints, 2014-2024
4. The Prostate Cancer Drugs Market 2014-2024
4.1 The Prostate Cancer Drugs Market: Increasing Choice of Drugs will Mean Higher Competition
4.2 The Prostate Cancer Drugs Market, 2013
4.3 Leading Prostate Cancer Drugs: Market Forecast, 2014-2024
4.3.1 The Market Shares of Leading Prostate Cancer Drugs, 2014-2024
4.4 First Generation Chemotherapies
4.4.1 Taxotere (Sanofi)
4.4.1.1 Taxotere Sales, 2013
4.4.1.2 Taxotere Sales Forecast, 2014-2024
4.5 Second Generation Chemotherapies
4.5.1 Jevtana (Sanofi)
4.5.1.1 Jevtana Sales, 2013
4.5.1.2 Jevtana Sales Forecast, 2014-2024
4.6 First Generation Hormones
4.6.1 Casodex (AstraZeneca)
4.6.1.1 Casodex Sales, 2013
4.6.1.2 Casodex Sales Forecast, 2014-2024
4.6.2 Lupron (AbbVie)
4.6.2.1 Lupron Sales, 2013
4.6.2.2 Lupron Sales Forecast, 2014-2024
4.6.3 Zoladex (AstraZeneca)
4.6.3.1 Zoladex Sales, 2013
4.6.3.2 Zoladex Sales Forecast, 2014-2024
4.7 Second Generation Hormones
4.7.1 Zytiga (Johnson & Johnson)
4.7.1.1 Zytiga Sales, 2013
4.7.1.2 Zytiga Sales Forecast, 2014-2024
4.7.2 Xtandi (Medivation/ Astellas Pharma)
4.7.2.1 Xtandi Sales, 2013
4.7.2.2 Xtandi Sales Forecast, 2014-2024
4.8 Immunotherapies
4.8.1 Provenge (Dendreon Corporation)
4.8.1.1 Provenge Sales, 2013
4.8.1.2 Provenge Sales Forecasts, 2014-2024
4.9 Radiopharmaceuticals
4.9.1 Xofigo (Bayer)
4.9.1.1 Xofigo Sales, 2013
4.9.1.2 Xofigo Sales Forecast, 2014-2024
4.10 Other Drugs
4.11 Prostate Cancer Drugs Pipeline, 2014
4.11.1 Phase III Development
4.11.1.1 DCVax-Prostate (NorthWest Biotherapeutics)
4.11.1.2 Tookad Soluble (Steba Biotech)
4.11.1.3 ProstAtak (Advantagene)
4.11.1.4 Tasquinimod (Active biotech AB/Ipsen)
4.11.1.5 Custirsen (Oncogenex/ Teva)
4.11.1.6 Cabozantinib (Exelixis)
4.11.1.7 Prostvac (Bavarian Nordic)
4.11.2 Failed Phase III Drugs
4.11.2.1 Custirsen (OncoGenex)
4.11.2.2 Yervoy (Bristol Myers Squibb)
4.11.2.3 Orteronel (Millenium Pharmaceuticals)
4.11.3 Phase II development
4.11.3.1 GDC-0980 (Roche)
4.11.3.2 GDC-0068 (Roche)
4.11.3.3 PSMA ADC (Progenics Pharmaceuticals)
4.11.3.4 Galeterone (Tokai Pharmaceuticals)
4.11.3.5 OGX-427 (OncoGenex Pharmaceuticals)
4.11.3.6 ARN-509 (Johnson & Johnson)
4.11.3.7 Abituzumab (Dl7E6) (Merck)
4.11.3.8 Ipilimumab (Yervoy) (Bristol Myers Squibb)
4.11.4 Phase I
4.11.4.1 ASG-5ME (Agensys/Seattle Genetics)
4.11.4.2 EMD-525797 (EMD Serono)
4.11.4.3 MGAH22 (MacroGenics)
4.11.4.4 RG7450 (Roche)
4.11.4.5 BAY2010112 (Bayer Pharmaceuticals)
4.11.4.6 BX-201 (Bellicum Pharmaceuticals)
4.12 The Leading Companies in the Prostate Cancer Drugs Market, 2014
4.12.1 Johnson & Johnson (J&J)
4.12.1.1 Sales and Performance Analysis, 2013
4.12.1.2 Pharmaceutical Segment Sales Analysis, 2013
4.12.1.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.1.4 Pharmaceutical Segment R&D Performance Analysis, 2013
4.12.1.5 Recent M&A Activity
4.12.1.5.1 Acquisition of Aragon Pharmaceuticals
4.12.2 AstraZeneca
4.12.2.1 Sales and Performance Analysis, 2013
4.12.2.2 Pharmaceutical Segment Sales Analysis by Segment, 2013
4.12.2.3 Oncology Drugs Sales and Performance Analysis, 2013
4.12.2.4 R&D Performance Analysis, 2013
4.12.3 Sanofi
4.12.3.1 Sales and Performance Analysis, 2013
4.12.3.2 Sales and Performance Analysis by Segment, 2012
4.12.3.3 Oncology Sales and Performance Analysis, 2013
4.12.3.4 R&D Performance Analysis, 2013
4.12.3.5 Oncology Pipeline Portfolio
4.12.4 AbbVie
4.12.4.1 Sales and Performance Analysis, 2013
4.12.4.2 R&D Performance Analysis, 2013
4.12.4.3 Oncology Portfolio Pipeline Products, 2013
5. The Prostate Cancer Devices Market 2014-2024
5.1 The Prostate Cancer Devices Market 2013
5.2 The Prostate Cancer Devices Market Forecast, 2014-2024
5.2.1 The Market Shares of Leading Prostate Cancer Devices Submarkets, 2014-2024
5.3 The Brachytherapy Market, 2014-2024
5.4 The Radical Prostatectomy Market 2014-2024
5.4.1 Intuitive Surgical’s da Vinci Surgical System will Drive Market Growth
5.5 The External Beam Radiation Therapy Market, 2014-2024
5.6 The HIFU Market, 2014-2024
5.7 The Cryotherapy Market, 2014-2024
5.8 Leading Companies in the Prostate Cancer Devices Market 2014-2024
5.8.1 Varian Medical Systems
5.8.1.1 Sales and Performance Analysis, 2013
5.8.1.2 Oncology Segment Sales Analysis, 2013
5.8.1.3 Sales Analysis by Region, 2013
5.8.1.4 R&D Performance Analysis, 2013
5.8.1.5 Key Oncology Products, 2013
5.8.1.6 Varian and Siemens Partnership: Shaping the Future of Cancer Care
5.8.2 Elekta
5.8.2.1 Sales and Performance Analysis, 2013
5.8.2.2 Sales and Performance Analysis by Region, 2012
5.8.2.3 Elekta and Philips Establish Research Consortium
5.8.2.4 Product Launch and Development, 2013
5.8.3 Theragenics Corporation (acquired by Juniper)
5.8.3.1 Theragenics Sales Performance Analysis, 2012
5.8.3.2 Theragenics Sales Performance by Operation, 2012
5.8.3.3 Theragenics sales and Performance Analysis by Business Unit, 2012
5.8.3.4 Mergers and Acquisitions
5.8.3.4.1 Juniper’s acquisition of Theragenics
5.8.3.4.2 Acquisition of Needle Tech Products
5.8.3.4.3 Acquisition of Galt Medical
5.8.3.4.4 Acquisition of CP Medical
6. The Leading National Markets 2014-2024
6.1 Regional Breakdown of the Prostate Cancer Therapeutics Market, 2013
6.2 The Prostate Cancer Therapeutics Market: Regional Forecast, 2014-2024
6.2.1 Market Shares Forecasts of Leading National Prostate Cancer Therapeutics
Markets, 2014-2024
6.3 The US Prostate Cancer Therapeutics Market 2014-2024: Largest National Market
6.4 The European Prostate Cancer Therapeutics Market, 2013
6.4.1 The European Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.1 The German Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.2 The French Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.3 The UK Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.4 The Spanish Prostate Cancer Therapeutics Market, 2014-2024
6.4.1.5 The Italian Prostate Cancer Therapeutics Market, 2014-2024
6.5 The Japanese Prostate Cancer Therapeutics Market, 2014-2024
6.6 The Brazilian Prostate Cancer Therapeutics Market, 2014-2024
6.7 The Russian Prostate Cancer Therapeutics Market, 2014-2024
6.8 The Indian Prostate Cancer Therapeutics Market, 2014-2024
6.9 The Chinese Prostate Cancer Therapeutics Market, 2014-2024
6.10 The South Korean Prostate Cancer Therapeutics Market, 2014-2024
6.11 The Mexican Prostate Cancer Therapeutics Market, 2014-2024
6.12 The Rest of the World Prostate Cancer Therapeutics Market, 2014-2024
7. Qualitative Analysis of the Prostate Cancer Therapeutics Market 2014-2024
7.1 SWOT Analysis, 2014-2024
7.2 Strengths
7.2.1 Prostate Cancer is a High Profile Disease
7.2.2 Rapidly Expanding Ageing Population
7.2.3 Targeted Therapies can Command Premium Prices
7.2.4 Strong R&D Pipeline
7.2.5 Successful Launches through Partnerships between Small/Big Pharma Companies
7.2.6 Use of Off-label Drugs is Common
7.3 Weaknesses
7.3.1 Prostate Cancer Drugs are Expensive
7.3.2 R&D Failures in Late-stage Development
7.3.3 Controversy Over the Value of New Prostate Cancer Devices
7.3.4 U.S Medical Excise Tax
7.4 Opportunities
7.4.1 Rising Incidence of cancer
7.4.2 Emerging National Markets will Drive Growth
7.4.3 Stem Cells Offer Promise
7.4.4 Advances in Diagnostic Technologies: CTC as a Biomarker
7.5 Threats
7.5.1 Concerns about Efficacy and Toxicity of Drugs
7.5.2 Who will Pay for the High Cost of Drugs and Devices?
7.5.3 Governments Decreasing Healthcare Spending
7.5.4 Increase in Generic Competition
7.5.5 Increase in the Practice of ‘Active Surveillance’
7.6 Porter’s Five Force Analysis
7.6.1 Rivalry Among Competitors [High]
7.6.2 Threat of New Entrants [High]
7.6.3 Power of Suppliers [Low]
7.6.4 Power of Buyers [High]
7.6.5 Threat of Substitutes [Low]
8. Expert Opinions
8.1 Professor Malcolm Mason, Cancer Research UK’s Prostate Cancer Expert
8.1.1 Factors Affecting the Growth of Prostate Cancer
8.1.2 Prostate Cancer: To Treat or Not to Treat?
8.1.3 Alternatives to PSA Testing
8.1.4 A Common Option for Early Stage Prostate Cancer: Radical Prostatectomy
8.1.5 Large Number of Clinical Trials Studying Prostate Cancer
8.1.6 Combination Therapy: Better Survival Rates
8.1.7 Novel Prostate Cancer Drugs: A Question of Cost
8.2 Interview with Hans Kolam, Chief Financial Officer and Helen Tuvesson, Chief Scientific Officer, Active Biotech
8.2.1 Tasquinimod: Phase III Pre-Chemotherapy Study
8.2.2 Tasquinimod: An Innovative Mode of Prostate Cancer Treatment
8.2.3 Active Biotech/Ipsen: Partnerships are Pivotal for Oncology Drug Development
8.2.4 Tasquinimod: Other Indications in the Pipeline
8.2.5 Competitive Landscape of the Prostate Cancer Drugs Market
8.2.6 The Drivers of Growth in the Prostate Market
8.3 Dr. Estuardo Aguilar-Cordova, Co-founder, CEO and Chairman, Advantagene
8.3.1 ProstAtak’s Mechanism for Prostate Cancer Prevention
8.3.2 ProsAtak’s Market Size
8.3.3 Immunotherapy: The Future for Cancer Treatment
8.3.4 Active Surveillance: A growing Trend
9. Conclusions
9.1 The Prostate Cancer Therapeutics Market, 2014-2024
9.2 The US Will Remain the Largest National Market from 2014 to 2024
9.3 Concluding Remarks
【レポート販売概要】
■ タイトル：世界の前立腺がん治療市場予測：前立腺がん治療薬、前立腺がん治療デバイス■ 英文：The Prostate Cancer Therapeutics Market 2014-2024
Opportunities for Leading Companies
■ 発行日：2014年7月
■ 調査会社：visiongain
■ 商品コード：VISG409047
■ 調査対象地域：グローバル
- 遅発性ジスキネジア(Tardive Dyskinesia)：世界の治験レビュー（2015年上半期版）Tardive Dyskinesia Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Tardive Dyskinesia Global Clinical Trials Review, H1, 2015" provides data on the Tardive Dyskinesia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Tardive Dyskinesia. It includes an overview of the trial numbers and their recruitme …
- 世界のUCaaS（Unified Communication as a service）市場動向（2012-2016）TechNavio's analysts forecast the Global Unified Communication as-a-service (UCaaS) market to grow at a CAGR of 25.46 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing need for centralized management. The Global Unified Communication as-a-service (UCaaS) market has also been witnessing the adoption of cloud-based enterprise services. How …
- 無人機（UAV）ペイロード及びサブシステムの世界市場2016-2026Visiongain's 302 page report assesses that the global UAV Payloads & Subsystems market will reach $5.2bn in 2016. The report indicates that the market is set to grow as nations seek to sustain and enhance their capabilities as the probability for symmetric warfare increases. It is therefore critical that your strategic planning is timely and your forecasting plans are in place to take advantage of …
- 移動通信デバイスの世界市場This report describes the cellular connected device ecosystem, in terms of offerings and related business models. It describes the main drivers and barriers for market take-off. It also provides forecasts in volume and in value for the laptops and tablets markets for nine countries.
- 民間航空機用座席の世界市場2019-2023Global Commercial Aircraft Seating Market: About this market Technavio’s commercial aircraft seating market analysis considers sales from economy class, business class, premium economy class, and first-class. Our analysis also considers the sales of commercial aircraft seating in APAC, Europe, North America, South America, and MEA. In 2018, economy class segment had a significant market share, and …
- 電気生理学アブレーション用カテーテル（医療機器）のグローバル市場（2012-2018）Global Electrophysiology (EP) Ablation Catheters sector is projected to reach US$341 million by 2016. The North America accounts for nearly 34% (2015) of the global share while Europe claims approximately 30% (2018). Asia-Pacific is the fastest growing region with a CAGR of 9.2% driving a market value of US$83 million by 2015. On a global scale, projections for Radiofequency (RF) EP Ablation Cathe …
- QEP Resources, Inc.社の石油・ガス開発・生産動向及びコスト分析（2013年第4四半期）QEP Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis - Q4, 2013 Summary QEP Resources, Inc. Oil & Gas Exploration and Production Operations and Cost Analysis is the latest report from GlobalData, the industry analysis specialists, that offers comprehensive information on the operational and financial performance of the company. The report is an essential source for …
- 世界の半導体（シリコン）IPコア市場動向及び予測(2013 – 2020)Today’s System-on-Chips and advanced ICs integrate a great variety of advanced functionality into a single device to offer superior performance, with more IP cores on a single chip. The rapidly growing consumer applications demand extensively integrated functionality and competitive features, such as optimization between performance and power consumption, all at an aggressive price point. As new p …
- 化学センサーの世界市場About Chemical Sensors Chemical sensors transfer chemical signals to electrical signals through transducers incorporated in a sensitive layer. They help to analyze the chemical composition of a sample, which is either in a liquid or gaseous form. Chemical sensors consist of a receptor and a transducer, which are controlled by kinetics and thermodynamic chemical reactions and operate in real time. …
- 回路遮断器・リレー・ヒューズの世界市場2016-2020About Circuit Breaker Fuse and Relay Circuit breakers are electrical switches that protect electric circuit from short-circuiting and overloading. These switches are designed to detect overloading and cut power supply automatically. Fuse prevents electricity overload by melting a wire inside the circuit and thus protecting all electrical and electronic devices connected to the circuit. Switches th …
- 整形外科用ソフトウェアの世界市場：インサイト、市場機会、市場シェア、市場予測The global orthopedic software market is estimated to reach $24645 million by 2022 and is expected to grow at CAGR of 6.1% during 2016-2022. The orthopedic software market is segmented on the basis of application, mode of delivery, product and geography. The application segment is segmented into orthopedic surgery, joint replacement, fracture management and pediatric assessment. The mode of delive …
- IT資産管理（ITAM）の世界市場2016-2020About IT Asset Management ITAM software allows organizations to efficiently manage their computer hardware and software inventories, correlate assets to contracts and financial records such as software licenses and equipment leases, and detect and prevent IT and regulatory risks to their various technology components. The software ensures that all of the IT systems in the organization are operatin …
- スナックバーのアメリカ市場2020-2024Snack Bars Market in the US 2020-2024Technavio has been monitoring the snack bars market in the US and it is poised to grow by USD 806.08 mn during 2020-2024, progressing at a CAGR of 2% during the forecast period. Our reports on snack bars market in the US provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 …
- 免疫タンパク質診断検査の世界市場2015-2019Immunoproteins are blood proteins that are used as analytes for different disease diagnostic assays like ELISA, CLIA, immunoturbidity assay, and RIA. The market for immunoprotein diagnostic testing is positively influenced by factors like the growing elderly population and the increased incidence and prevalence of chronic diseases. These factors foster the prospects for growth in this market and r …
- 自動車ウインチ装置（AWS）の世界市場About Automotive Winches System An automotive winch is defined as a system that is used for towing a vehicle. The system is mostly used by SUVs, pickup trucks, and other commercial vehicles, wherein a towing mechanism is used that envelopes the wire around the drum while keeping the necessary tension on it. Technavio’s analysts forecast the global automotive winches system market to grow at a CAGR …
